West Pharmaceutical Services, Inc. - 2006 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: West Pharmaceutical Services, Inc.
Reporting Period: Fiscal year ended December 31, 2006.
Business Overview: A global manufacturer of components and systems for injectable drug delivery and plastic packaging for healthcare, personal care, and consumer markets. The company operates through two primary segments: Pharmaceutical Systems (stoppers, seals, syringe components) and Tech Group (custom contract manufacturing for medical and consumer products).
Key Developments: The 2006 results include a full year of operations from three major 2005 acquisitions: Tech Group, Inc. (TGI), Medimop Medical Projects, Ltd., and Monarch Analytical Laboratories, Inc.
Key Financial Metrics (2006)
| Metric | 2006 Value | 2005 Value |
|---|---|---|
| Net Sales | $913.3 million | $699.7 million |
| Gross Profit | $261.8 million | $193.8 million |
| Gross Margin | 28.7% | 27.7% |
| Operating Profit | $101.0 million | $73.4 million |
| Operating Margin | 11.1% | 10.5% |
| Net Income | $67.1 million | $46.4 million |
| Diluted EPS (Continuing Ops) | $1.83 | $1.41 |
| Operating Cash Flow | $139.4 million | $85.6 million |
| Capital Expenditures | $90.3 million | $54.1 million |
| Total Debt | $236.3 million | $281.0 million |
| Debt-to-Invested Capital | 36.0% | 45.0% |
| Cash and Equivalents | $47.1 million | $48.8 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 30.5% to $913.3 million. This growth was driven by the timing impact of 2005 acquisitions (13.4 percentage points), favorable foreign currency translation (0.6 percentage points), and organic volume growth (16.5%).
- Profitability: Operating profit rose 37.5% to $101.0 million. Gross margins improved in both segments due to favorable product mix and efficiency gains, which offset higher raw material and utility costs.
- Debt Refinancing: The company prepaid $100 million of senior notes (6.81% interest) and issued new Euro-denominated notes at lower rates (approx. 4.34% weighted average), reducing annual pre-tax financing costs by approximately $2.5 million. This incurred a one-time loss on debt extinguishment of $5.9 million.
- Discontinued Operations: Income from discontinued operations was $5.6 million in 2006, primarily due to a $4.0 million tax benefit from the resolution of a claim related to the 2001 sale of the former contract manufacturing business.
- Accounting Changes: The company adopted SFAS 158 (pension accounting), resulting in a $19.7 million reduction in shareholders' equity. Additionally, inventory costing for certain U.S. inventory was changed from LIFO to FIFO, applied retrospectively.
Guidance, Outlook, and Risks
- Capital Spending: Management estimates 2007 capital spending to be approximately $130 million, with over 80% supporting the Pharmaceutical Systems segment to expand capacity in Europe, Asia, and the U.S.
- Expansion Plans: The company plans to establish a manufacturing presence in the People's Republic of China, targeting a new plastic injection-molding plant completion in 2009 and a rubber components plant by 2011.
- Key Risks:
- Customer Concentration: The top 10 customers accounted for 36.4% of consolidated net sales; no single customer exceeded 10%.
- Raw Materials: Profitability is sensitive to the cost of elastomers, aluminum, and plastics. The company relies on single-source suppliers for critical materials, creating supply chain risks.
- Regulatory: Operations are subject to strict FDA and international regulations. Delays in customer product approvals (e.g., Exubera inhalation device) can impact demand.
- Foreign Exchange: Approximately 49% of sales are outside the U.S., exposing the company to currency fluctuations.
- Unusual Items: A $2.5 million asset impairment charge was recorded in the Pharmaceutical Systems segment related to a reconstitution product line with reduced projected orders.
Investor Verification Checklist
- Acquisition Integration: Verify the full-year contribution of TGI, Medimop, and Monarch to ensure organic growth rates are accurately assessed.
- Debt Structure: Confirm the impact of the new Euro-denominated debt on future interest expense and foreign exchange exposure.
- Capacity Constraints: Assess the timeline for new capacity additions in Europe and Asia against the reported order backlog of $250.1 million.
- Pension Obligations: Review the impact of the SFAS 158 adoption and the amendment to the U.S. defined benefit plan (frozen benefits) on future cash flow requirements.
- Exubera Dependency: Monitor the commercial success of the Exubera inhalation device, as the Tech Group segment is a primary contract manufacturer for this product.